- Sep 10, 2020Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement...
Aug 6, 2020Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT
- Aug 6, 2020- Phase 1a Clinical Trial to Begin in Q4 2020
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information...
- Jul 30, 2020Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6
May 14, 2020- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT -